Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A systematic literature review and bayesian meta-analysis of oral vancomycin primary prophylaxis forAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025
   Article
2. Controversies in the Prevention and Treatment ofMicroorganisms · 2023
   Review
3. Gut microbiome health and dysbiosis: A clinical primer.Pharmacotherapy · 2022
   Review
4. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention ofAntibiotics (Basel, Switzerland) · 2022
   Review
5. The Detrimental Effects of Oral Vancomycin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
   Article

Corrections and comments

• Comment on
  Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.2020

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as